ALAMAR BIOSCIENCES INC
ALMRNASDAQTrading Snapshot
- Day Range
- $32.21 – $33.29
- 52-Week Range
- $18.85 – $38.54
- Volume
- $3.87B
- Avg Volume
- $3.42B
- Shares Outstanding
- 69.3M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $74M
- Last Q Revenue
- $29M
- P/E Ratio
- -61.5
- P/S Ratio
- 40.8x
- EPS (TTM)
- $-0.59
- Dividend Yield
- 0.00%
Why Investors Own ALMR
- ✓High-growth profile — revenue up +47.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALAMAR BIOSCIENCES INC
ALMR
StockOtter · stockotter.spaceAbout ALAMAR BIOSCIENCES INC
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be p
Alamar Biosciences: Promising But Expensive Proteomics Growth
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also de
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences (NASDAQ: ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company